Skip to main content

This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content may only be relevant to HCPs practising in Great Britain (England, Scotland and Wales) according to product availability. This website is optimised for desktop use, and some features may perform differently on mobile devices.

Adverse event reporting can be found at the bottom of the page.

Menu


Early presymptomatic autoimmune T1D (Stages 1 and 2) can be identified through testing for autoantibodies (AAbs) in the blood1,2

Autoimmune T1D detection in the clinic

Collection of a blood sample for testing can be done by a simple finger prick.3 The four AAb tests recommended by the American Diabetes Association (ADA) Standards of Care are:4

icon gada

GADA (Glutamic acid decarboxylase 65 autoantibody)

  • Common first detected AAb in children aged ≤15 years
  • Adult-onset cases mostly present with GADA
  • Associated with slower T1D progression
  • Often found as a single AAb, especially in adults
icon iaa

IAA (Insulin autoantibody)

  • Common first detected AAb in young children
  • More commonly detected in younger children
  • Frequency declines with increasing age
  • Not informative for those treated with insulin
icon ia-2a

IA-2A (Insulinoma-associated antigen 2 autoantibody)

  • Associated with more advanced islet autoimmunity
  • Associated with faster T1D progression to stage 3
  • IA-2A is also called islet cell autoantigen 512 (ICA512)
icon zntba

ZnT8A (Zinc transporter 8 autoantibody)

  • Presence can improve risk stratification in people with single GADA+, IAA+ or IA-2A+ status

Find out more about who to test here.
 

Glycaemic parameters to look for in autoimmune T1D


The British Society for Paediatric Endocrinology and Diabetes (BSPED), the International Society for Pediatric and Adolescent Diabetes (ISPAD), and the World Health Organization (WHO) outline the following diagnostic tests and glycaemic parameters for the stages of TID.3–6


Blood test

Placeholder
Fasting plasma glucose (FPG)
120-min oral glucose tolerance test (OGTT)
Glycated haemoglobin (HbA1c)

Stage 1

Normoglycaemia
<5.6 mmol/L
<7.8 mmol/L
<39 mmol/mol
(<5.7%)

Stage 2

Dysglycaemia
5.6–6.9 mmol/L
7.8–11.0 mmol/L
39–47 mmol/mol
(5.7–6.4%)

Stage 3

Hyperglycaemia
≥7.0 mmol/L
≥11.1 mmol/L
≥48 mmol/mol
(≥6.5%)

Adapted from Besser REJ, et al. 2025.6

The number of AAbs detected, glycaemic status, and age may be used to guide frequency of monitoring.7

Find out more about monitoring guidance here.

Testing and monitoring handbook

Screening and monitoring for autoimmune T1D

Most screening initiatives for presymptomatic autoimmune T1D (Stages 1 and 2) are being performed in the context of research, but may become standard of care in parts of the world.3

In the UK, adults and children can be screened for autoimmune T1D through enrolment in research studies:8,9

  • T1DRA Adults aged 18-70 years old
  • ELSA Children aged 2-17 years old

ELSA and T1DRA are research studies independent of Sanofi.

Testing should be coupled with education and ongoing monitoring for those identified with islet AAbs.3

UK (BSPED) and international (ISPAD) guidance for adult and paediatric patients recommend regular glycaemic monitoring in all patients who have tested positive for islet AAbs.3,4,6

INDICATION: TZIELD is indicated to delay the onset of Stage 3 T1D in adult and paediatric patients 8 years of age and older with Stage 2 T1D.10

Get in Touch with Us

Questions? Leave your details and we'll reach out to you at your preferred time.

Get in touch

AAb, autoantibody; ADA, American Diabetes Association; BSPED, British Society for Paediatric Endocrinology and Diabetes; FPG, fasting plasma glucose; GADA, glutamic acid decarboxylase 65 autoantibody; HbA1c, glycated haemoglobin; IAA, insulin autoantibody; IA-2A, insulinoma-associated antigen 2 autoantibody; ISPAD, International Society for Pediatric and Adolescent Diabetes; OGTT, oral glucose tolerance test; T1D, Type 1 diabetes; WHO, World Health Organization; ZnT8A, zinc transporter 8 autoantibody.

  1. Sims EK, et al. Diabetes. 2022; 71: 610–623.
  2. Ospelt E, et al. Clin Diabetes. 2024; 42(1): 17–26.
  3. Haller MJ, et al. Horm Res Paediatr. 2024; 97(6): 529–545.
  4. Phillip M, et al. Diabetes Care. 2024; 47(8): 1276–1298.
  5. World Health Organization. (2019). Classification of diabetes mellitus. Available at: https://www.who.int/publications/i/item/classification-of-diabetes-mellitus. Accessed May 2026.
  6. Besser REJ, et al; BSPED. Diabet Med. 2025; 42(11): e70117.
  7. Simmons KMW, et al. Diabetes Technol Ther. 2023; 25(11): 790–799.
  8. The Type 1 Diabetes Risk in Adults (T1DRA) Study. Available at: https://t1dra.bristol.ac.uk/. Accessed May 2026.
  9. The ELSA Study. Available at: https://www.elsadiabetes.nhs.uk/. Accessed May 2026.
  10. TZIELD® (teplizumab) UK Summary of Product Characteristics.

MAT-XU-2500762 (v3.0) | April 2026

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to the Sanofi drug safety department on Tel: +44 (0) 800 0902 314. Alternatively, send via email to UK-drugsafety@sanofi.com